A(2A) receptor dependent and A(2A) receptor independent effects of extracellular adenosine on murine thymocytes in conditions of adenosine deaminase deficiency

Blood

Volumn 95, Issue 12, 2000, Pages 3859-3867

  Apasov, Sergey ^b   Chen, Jiang Fan ^b   Smith, Patrick ^b   Sitkovsky, Michail ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE DEAMINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; COMBINED IMMUNODEFICIENCY; ENZYME ACTIVITY; LYMPHOCYTE DIFFERENTIATION; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; THYMOCYTE;

EID: 0034660478     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.12.3859     Document Type: Article

References (41)

1. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972;2:1067-1069.
2. Hirschhorn R. Adenosine deaminase deficiency: molecular basis and recent developments. Clin Immunol Immunopathol. 1995;76:S219-S227.
3. Hershfield MS, Mitchell, BS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency In: The Molecular and Metabolic Basis of Inherited Diseases. New York, NY: McGraw-Hill; 1995;1725-1768.
4. Ullman B, Levinson BB, Hershfield MS, Martin DW. A biochemical genetic study of the role of specific nucleoside kinases in deoxyadenosine phosphorylation by cultured human cells. J Biol Chem. 1981;256:848-852.
5. Kellems RE, Yeung C-Y, Ingolia DE. Adenosine deaminase deficiency and severe combined immunodeficiencies. Trends Genet. 1985;1:278.
6. Carson DA, Kaye J, Wasson, DB. The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts. J Immunol. 1981;126:348-352.
7. Doherty P, Pan S, Milloy, J, et al. Adenosine deaminase and thymocyte maturation. Scand J Immunol. 1991;33:405-410.
8. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996;86:147-157.
9. Apasov S, Sitkovsky M. The extracellular versus intracellular mechanisms of inhibition of TCR-triggered activation in thymocytes by adenosine under conditions of inhibited adenosine deaminase. Int Immunol. 1999;11:179-189.
10. Apasov SG, Koshiba M, Chused TM, Sitkovsky MV. Effects of extracellular ATP and adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptors. J Immunol. 1997;158:5095-5105.
11. Zenzer TV. Formation of adenosine 3′,5′-monophosphate from adenosine in mouse thymocytes. Biochim Biophys Acta. 1975;404:202-213.
12. Schwartz AL, Stern RC, Polmar, SH. Demonstration of an adenosine receptor on human lymphocytes in vitro and its possible role in the adenosine deaminase-deficient form of severe combined immunodeficiency. Clin Immunol Immunopathol. 1978;9:499-505.
13. Kizaki H, Suzuki K, Tadakuma T, Ishimura Y. Adenosine receptor-mediated accumulation of cyclic AMP-induced T lymphocyte death through internucleosomal DNA cleavage. J Biol Chem. 1990;265:5280-5284.
14. McConkey DJ, Nicotera P, Orrenius S. Signalling and chromatin fragmentation in thymocyte apoptosis. Immunol Rev. 1994;142:343-363.
15. +-mediated mechanisms. Biochem J. 1994;304:877-885.
16. + thymocytes in vivo by anti-CD3 or 5′-(N-ethyl)-carboxamide adenosine is blocked by glucocorticoid receptor antagonist RU-486. Eur J Immunol. 1993;23:1246-1250.
17. Huang S, Koshiba M, Apasov S, Sitkovsky M. Role of A2a adenosine receptor-mediated signaling in inhibition of T cell activation and expansion. Blood. 1997;90:1600-1610.
18. Chused TM, Apasov S, Sitkovsky MV. Murine T lymphocytes modulate activity of an ATP-activated p2z-type purinoreceptor during differentiation. J Immunol. 1996;157:1371-1380.
19. Vacchio MS, Papadopoulos V, Ashwell JD. Steroid production in the thymus: implications for thymocyte selection. J Exp Med. 1994;179:1835-1846.
20. Olsson RA. Adenosine receptors in the cardiovascular system. Drug Dev Res. 1996;39:301-307.
21. Belardinelli L, Curtis A, Bertolet B. Cardiac electrophysiology of adenosine: antiarrhythmic and proarrythmic actions. In: Jacobson KA, Janvis MF, eds. Purinergic Approaches in Experimental Therapeutics. New York, NY: John Wiley; 1997; 185.
22. Olah ME, Stiles GL. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol. 1995;35:581-606.
23. Jacobson KA, von Lubitz DK, Daly JW, Fredholm BB. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci. 1996;17:108-113.
24. Jacobson KA, Hoffmann C, Cattabeni F, Abbracchio MP. Adenosine-induced cell death: evidence for receptor-mediated signalling apoptosis. Apoptosis. 1999;4:197-211.
25. Abbracchio MP. P1 and P2 receptors in cell growth and differentiation. Drug Dev Res. 1996; 39:393-406.
26. Kohno Y, Sei Y, Yoshiba M, Kim HO, Jacobson KA. Induction of apoptosis in HL-60 human promyelocytic leukemia cells by selective adenosine A3 receptor agonists. Biochem Biophys Res Commun. 1996;219:904-910.
27. Sei Y, von Lubitz DK, Abbracchio MP, Ji XD, Jaconsob KA. Adenosine A3 receptor agonist-induced neurotoxicity in rat cerebellar granule neurons. Drug Dev Res. 1997;40:267-273.
28. Barbieri D, Abbracchio MP, Salvioli S, et al. Apoptosis by 2-chloro-e′-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem Int. 1998;32:493-504.
29. Darzynkiewicz Z, Bruno S, Del Bino G, et al. Features of apoptotic cells measured by flow cytometry. Cytometry. 1992;13:795-808.
30. Martin SJ, Reutelingsperger CPM, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidilserine is a general feature of apoptosis regardless of initiating stimulus: inhibition by overexpression of bcl-2 and abl. J Exp Med. 1995;182:1545.
31. McConkey DJ, Orrenius S, Jondal M. Agents that elevate cAMP stimulate DNA fragmentation in thymocytes. J Immunol. 1990;145:1227-1230.
32. Koshiba M, Rosin DL, Hayashi N, Linden J, Sitkovsky MV. Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells: flow cytometry studies with anti-A2A receptor monoclonal antibodies. Mol Pharmacol. 1999;55:614-624.
33. Koshiba M, Kojima H, Huang S, Apasov S, Sitkovsky MV. Memory of extracellular adenosine/ A2a purinergic receptor-mediated signalling in murine T cells. J Biol Chem. 1997;272:25881-25889.
34. Apasov S, Koshiba M, Redegeld F, Sitkovsky M. Role of extracellular ATP and P1 and P2 classes of purinergic receptors in T-cell development and cytotoxic T lymphocyte effector functions. Immunol Rev. 1995;146:5-19.
35. Robey E, Fowlkes BJ. Selective events in T cell development. Annu Rev Immunol. 1994;12:675-705.
36. Cibotti R, Punt JA, Dash KS, Sharrow S, Singer A. Surface molecules that drive T cell development in vitro in the absence of thymic epithelium and in the absence of lineage-specific signals. Immunity. 1997;6:245-255.
37. Downey JM. Ischemic preconditioning: nature's own cardioprotective intervention. Trends Cardiovasc Med. 1992;2:170-176.
38. von Lubitz DK, Lin RC, Beenhakker M, Boyd M, Bischofberger N, Jacobson KA. Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. Eur J Pharmacol. 1996;316:171-179.
39. Knutsen LJ, Murray TF. Adenosine and ATP in epilepsy. In: Jacobson KA, Jarvis MF, ads. Purinergic Approaches in Experimental Therapeutics. New York, NY: John Wiley; 1997:423.
40. Chen J-F, Huang Z, Ma J, et al. Focal ischemic brain injury is reduced in mice lacking A2a adenosine receptors. Ann Neurol. 1999;46:445.
41. Blackburn MR, Datta SK, Kellems RE. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem. 1998;273: 5093-5100.